Previous Article | Next Article ![]()
Infection and Immunity, December 2007, p. 5924-5929, Vol. 75, No. 12
0019-9567/07/$08.00+0 doi:10.1128/IAI.01029-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Program in Infectious Diseases and Immunity,1 the School of Public Health, University of California, Berkeley, 140 Warren Hall, Berkeley, California 947202
Received 26 July 2007/ Returned for modification 5 September 2007/ Accepted 11 September 2007
|
|
|---|
|
|
|---|
B is primarily associated with inflammatory stimuli; however, mitogen-activated protein kinase (MAPK) signaling pathways are also involved in these processes (4). Pathogen modulation of MAPK pathways changes host cell responses through activation or repression of the signaling pathway, which can ultimately affect immune responses such as IL-8 production (6, 19).
Cytokines produced locally by Chlamydia-infected epithelial cells are postulated to be essential for the progression of the inflammatory response that leads to pathology and disease (22). Inflammatory cytokines are induced by Chlamydia trachomatis infection in vitro and in vivo (3, 16, 20) and include IL-8, a chemotactic attractant and activator of neutrophils that is associated with inflammation-mediated tissue damage (18). The markedly late induction of IL-8 (at 15 h postinfection [hpi]) and its dependence on bacterial growth and protein synthesis implicate direct intracellular interactions of bacteria and the host cell (1). Consistent with this hypothesis, IL-8 induction occurs only within inclusion-containing cells and is independent of exogenous factors in the supernatant before 48 hpi, signifying that chlamydial products within the host cell lead to this inflammatory response (1). This is termed the endogenous IL-8 response and precedes the very late amplification of IL-8 expression by IL-1
following cell lysis at 72 hpi (1, 20).
While inflammatory cytokines are essential components of the host innate immune response to chlamydial infection, how they are induced and maintained is not known. Characterization of the IL-8 promoter revealed that the AP-1 and C/EBP (NFIL6) elements are necessary for the full transcriptional response of IL-8 after C. trachomatis infection (1). The transcription factors that bind to these sites are regulated by the host extracellular signal-regulated kinase (ERK), p38, and Jun N-terminal kinase (JNK) MAPK signaling pathways (10, 13). Consequently, the IL-8 response by the host cell to C. trachomatis infection may be due to bacterium-host interactions causing up-regulation of one or more of these cellular signaling pathways. ERK phosphorylation and activation occur later during C. trachomatis infection and are necessary for host lipid uptake by the bacterium (23). ERK pathway activation is maintained throughout the course of infection during the time that the endogenous IL-8 response occurs in C. trachomatis-infected cells. Thus, ERK is a likely candidate as a cellular signaling pathway through which IL-8 is induced after C. trachomatis infection.
The purpose of this research was to identify the host signaling pathways necessary for and leading to induction of the endogenous IL-8 response. Not only is IL-8 an essential inflammatory factor, but elucidation of the mechanism of its up-regulation will define how Chlamydia growth and bacterial products modulate the host cell response. In this study, we show that IL-8 mRNA induced by C. trachomatis is dependent on the ERK signaling pathway and that ERK activation occurs concurrently with IL-8 mRNA production, suggesting that a late and constant bacterial signal induces this response.
|
|
|---|
Growth of Chlamydia. C. trachomatis L2/434/Bu was cultured in L929 murine fibroblast cells and isolated as previously described (1). C. trachomatis D/UW-3/Cx was cultured in HeLa 229 cells for 48 h and harvested as described previously (1); however, it was not passed over 30% RenoCal-76 but was suspended directly in sucrose-phosphate-glutamic acid and frozen at –80°C. Chlamydia infections of HeLa and Hep2 cells were performed as described previously (1), using 90% confluent cell monolayers with an approximate multiplicity of infection of 2.
QPCR. Quantitative PCR (QPCR) analysis was performed according to the method of Buchholz and Stephens (1) and normalized as previously described (15). QPCR to quantify chlamydial genomes was performed according to a previously described method (11), with modification. Briefly, 26-µl reaction mixtures contained 200 nM of each primer, a 400 µM concentration of each deoxynucleoside triphosphate, 150 nM 6-carboxyfluorescein probe, 300 nM Cy5 probe, 5 mM MgCl2, and 2.5 units Platinum Taq (Invitrogen) and were run at 95°C for 10 min, followed by 35 cycles at 95°C (15 s), 55°C (5 s), and 72°C (10 s) on a Smartcycler machine (Cepheid, Sunnyvale, CA). The following primers were used: for 16S RNA, 5'-CGCCTGAGGAGTACACTCGC-3' and 5'-CCAACACCTCACGGCACGAG-3'; and for beta-globin, 5'-TACCCTTGGACCCAGAGGTTCTTTGA-3' and 5'-TCAGGATCCACGTGCAGCTTGTCA-3'. The following probes were used: a 16S probe with a 5' Cy5 fluorophore and a 3' BHQ2 quencher (5'-CACAAGCAGTGGAGCATGTGGTTTAA-3') (IDT) and a beta-globin probe with a 5' 6-carboxyfluorescein fluorophore and a 3' IBFQ quencher (5'-ATGGCAAGAAAGTGCTCGGTGCCTTT-3') (IDT). The number of Chlamydia genomes per well was quantified by comparison to a standard curve of genomic L2 DNA, using cycle threshold values.
Immunoblotting. Cell lysate was harvested with sodium dodecyl sulfate-polyacrylamide gel electrophoresis buffer, boiled, run in 10% sodium dodecyl sulfate-polyacrylamide gels, and transferred to nitrocellulose for probing with antibodies specific to phosphorylated or total protein. Phospho-p44/42 (ERK) MAPK monoclonal antibody, p44/42 MAPK antibody, phospho-MAPKAPK-2 antibody, p38 antibody, SAPK/JNK antibody, and phospho-SAPK/JNK antibody were all obtained from Cell Signaling Technology (Danvers, MA). Horseradish peroxidase-conjugated goat anti-mouse and horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (heavy plus light chains) secondary antibodies were purchased from Zymed (South San Francisco, CA).
Chemical inhibitors of MAPK pathways. Inhibitors of the ERK, JNK, and p38 pathways (Calbiochem, San Diego, CA) were diluted in dimethyl sulfoxide and added directly to culture supernatants after infection. The MEK1/2 inhibitor SL327 was used at a final concentration of 1 µM, the JNK II inhibitor SP600125 was used at a final concentration of 1 µM, and the p38 MAPK III inhibitor ML3403 was used at a final concentration of 2 µM, unless otherwise noted.
Statistical methods. The statistical significance of data was determined using two-tailed Student's t test.
|
|
|---|
![]() View larger version (27K): [in a new window] |
FIG. 1. Identification of MAPK pathway involvement in IL-8 up-regulation in response to C. trachomatis infection. (A) HeLa cells were infected or incubated in medium alone for 2 h. Fresh medium containing the appropriate MAPK inhibitor (MEK1/2 inhibitor, 1 µM; JNK inhibitor, 1 µM; p38 inhibitor, 2 µM) was then added, and total RNA was isolated at 30 hpi. The relative change in IL-8 mRNA compared to that in uninfected cells with similar inhibitor treatment was determined by QPCR as described in Materials and Methods. Data shown are averages ± standard deviations (SD) for three wells. Data are from one of three experiments. *, P < 0.03 compared to infected cells without inhibitor treatment. (B) HeLa cells were infected with C. trachomatis L2 for 30 h, with or without the MEK1/2 inhibitor of the ERK pathway. Data are from one of three experiments.
|
(Fig. 2B). Phosphorylation of MAPKAPK2, a substrate of p38 induced by IL-1
, was abolished by the specific chemical inhibitor of the p38 pathway (Fig. 2B). Phosphorylation of JNK induced by IL-1
was similarly reduced by the specific chemical, showing that the dose used was sufficient to functionally inhibit these pathways. The use of increasing doses of JNK and p38 MAPK inhibitors, of 1 and 10 µM and 2 and 20 µM, respectively, did not inhibit IL-8 mRNA induced by C. trachomatis infection (data not shown). Thus, we conclude that the ERK pathway is necessary for the up-regulation of IL-8 mRNA in response to C. trachomatis infection, while the JNK and p38 pathways are not activated or involved in the IL-8 response at this time.
![]() View larger version (26K): [in a new window] |
FIG. 2. Dose-dependent reduction in C. trachomatis-induced IL-8 by an inhibitor of the ERK pathway. (A) Increasing concentrations of the MEK1/2 inhibitor of the ERK MAPK pathway were added 90 min prior to total RNA harvest at 24 hpi. The relative change in IL-8 mRNA was determined as described in the legend to Fig. 1. Data shown are averages ± SD. Data are from one of two experiments. **, P = 0.012; *, P < 0.01 (compared to infected cells without inhibitor treatment). (B) C. trachomatis-infected cells were treated with 2 µM p38 inhibitor or 1 µM JNK inhibitor at 24 hpi. One nanogram (p38) or 4 ng (JNK) IL-1 was added for 20 min prior to harvest at 25.5 hpi. Data are from one of two experiments.
|
![]() View larger version (17K): [in a new window] |
FIG. 3. Late ERK pathway activation induces IL-8 response. C. trachomatis-infected HeLa cells were treated with 1 µM MEK1/2 inhibitor for 90 min prior to RNA isolation at 24 hpi (A) or from 1 h prior to 2 hpi, after which the inhibitor was removed, with RNA isolated at 24 hpi (B). The relative change in IL-8 mRNA compared to that in similarly treated uninfected cells was determined as described in the legend to Fig. 1. Data shown are averages ± SD. Data are from one of three experiments. *, P < 0.01. (C) C. trachomatis-infected cells were treated with 1 µM MEK1/2 inhibitor for 90 min prior to collection of lysate at 24 hpi. Data are from one of two experiments. DMSO, dimethyl sulfoxide.
|
![]() View larger version (12K): [in a new window] |
FIG. 4. Measurement of Chlamydia infection by QPCR. HeLa cells were infected with C. trachomatis L2 and treated with 1 µM or 10 µM MEK1/2 inhibitor or 100 µg/ml chloramphenicol immediately after removal of infection (gray bars), or treatment was added 90 min prior to DNA isolation at 24 hpi (white bars). Data shown are averages ± SD for three separate wells. Data are from one of two experiments. **, P < 0.05; *, P < 0.01 (compared to infected cells without inhibitor treatment).
|
![]() View larger version (20K): [in a new window] |
FIG. 5. ERK activation in HeP2 cells during C. trachomatis infection. (A) HeLa or HeP2 cells were concomitantly infected with C. trachomatis L2, and total RNA was harvested at 48 hpi. The relative change in IL-8 mRNA was determined as described in the legend to Fig. 1. Data shown are averages ± SD. Data are from one of two experiments. (B) Phosphorylation of ERK protein was determine by immunoblotting of C. trachomatis L2-infected HeLa or HeP2 cells. Data are from one of two experiments.
|
![]() View larger version (28K): [in a new window] |
FIG. 6. ERK activation by C. trachomatis serovar D infection. (A) HeLa cells were infected with C. trachomatis serovar D, and total RNA was isolated at 30 hpi. The relative change in IL-8 mRNA compared to that in similarly treated uninfected cells was determined as described in the legend to Fig. 1. Data shown are averages ± SD. *, P < 0.01 compared to infected cells without inhibitor treatment. Data are from one of two experiments. (B) C. trachomatis serovar D-infected HeLa cells were evaluated for ERK phosphorylation at 48 hpi. E, MEK1/2 inhibitor of ERK pathway; Cm, chloramphenicol. Data are from one of three experiments.
|
|
|
|---|
The MAPK (p38, JNK, and ERK) signaling pathways can induce IL-8 transcription, although the contribution of each varies depending on cell type or stimulus (9, 14). The ERK pathway is activated in C. trachomatis-infected epithelial cells at 12 hpi in a manner that can be inhibited by the addition of chloramphenicol (23; data not shown), while the JNK and p38 MAPK pathways are not activated in response to C. trachomatis infection (7). Analogous to the localization of IL-8 only within infected cells (1), it has been shown that phosphorylated ERK protein, which is necessary for lipid acquisition, is found only in infected cells, not in neighboring uninfected cells (23). Activation of the ERK pathway occurs at similar times as IL-8 up-regulation and thus was a likely candidate to be involved in the IL-8 response (1). A short incubation time of only 90 min with the ERK pathway inhibitor was sufficient to block IL-8 production induced by infection. Continuous activation of this pathway is necessary to maintain IL-8 production, similar to the need for constant bacterial protein synthesis in sustaining the response (1). Together, these data suggest that a bacterial product produced during chlamydial growth is responsible for inducing and maintaining the ERK pathway activation that leads to inflammatory IL-8 production.
ERK activation during C. trachomatis infection is necessary for host lipid uptake by bacteria (7, 23). Inhibiting the ERK MAPK pathway reduced the number of inclusion-forming units recovered from C. trachomatis infection (23). Since inhibiting the ERK pathway could reduce growth and because the IL-8 response to Chlamydia infection is dependent on growth, the effect on IL-8 mRNA levels could have been indirect. Although we employed concentrations of the inhibitor that did not cause reductions in the number of inclusion-forming units, as previously shown (23), we nevertheless controlled for an unexpected effect on growth by using two experimental strategies, First, we added the ERK pathway inhibitor for only 90 min prior to collecting RNA to limit the time that it could interfere with chlamydial growth and development. Second, through quantification of Chlamydia genomes, we could compare treated and untreated infections for reduced numbers of Chlamydia bacteria. It was found that a 1 µM concentration of the inhibitor did not affect C. trachomatis growth, as assessed by the number of genomes, at 24 hpi, while 22 h of incubation with 10 µM ERK pathway inhibitor caused a slight reduction in the number of C. trachomatis genomes per host cell compared to an untreated infection. These results are similar to those reported by Su et al. (23). Thus, the reduction in IL-8 mRNA seen using 1 µM ERK pathway inhibitor is due to direct involvement of the signaling pathway in mRNA induction, not to indirect effects of the inhibitor on chlamydial growth.
Pathogenic bacteria can stimulate host signaling pathways by interacting with pathway members or molecules upstream of the signaling pathway (6, 19). During C. trachomatis infection, Ras and Raf induce ERK activation (23). We also found that Raf1 is necessary for phosphorylation of ERK after infection by treating cells with a Raf1 inhibitor (data not shown). The exact bacterium-host interaction upstream of and leading to ERK MAPK pathway activation has not been discerned. As such, it is not known whether the IL-8 response serves the bacteria or is a by-product of ERK involvement in chlamydial acquisition of glycerophospholipids. Nevertheless, ERK involvement in the induction of inflammation is essential for pathogenesis and disease.
Intracellular pathogens must have close associations with their host cells in order to survive and propagate. These host-pathogen interactions are especially vital for the obligate intracellular pathogen Chlamydia, as interactions with the cell occur throughout the developmental cycle and are necessary for viable infectious progeny (8). Interactions with the cell may also lead to host recognition, response to infection, and induction of the innate immune response. Here we have described the host ERK signaling pathway that is stimulated during productive C. trachomatis infection and induces the inflammatory mediator IL-8. Characterizing how C. trachomatis infection alters the host cell response is important for understanding the mechanism by which the bacterium facilitates its intracellular development and the host cell responds to infection.
We thank Carolyn G. Conant for developing the QPCR assay to quantify chlamydial genomes.
Published ahead of print on 24 September 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»